US to establish lab network for combating 'superbugs'

Image
AFP Washington
Last Updated : Jun 01 2016 | 5:48 PM IST
US authorities have said they are establishing a network of labs that can respond quickly to antibiotic-resistant "superbugs", following America's first human case of a dangerous strain of E. Coli.
The announcement by the US Centers for Disease Control and Prevention came yesterday as authorities try to identify people who had contact with a 49-year-old woman in the eastern state of Pennsylvania whose urinary tract infection tested positive for E. Coli bacteria carrying the antibiotic-resistant mcr-1 gene.
Starting in the fall, the CDC will provide infrastructure and lab capacity for "seven to eight regional labs, and labs in all states and seven major cities/territories, to detect and respond to resistant organisms recovered from human samples," the agency said in a statement.
State labs will be able to detect changes in antibiotic resistance and report the findings to federal authorities, leading to faster and more effective investigations and "stronger infection control among patients to prevent and combat future resistance threats."
The Pennsylvania woman had not travelled abroad recently and officials do not know how she contracted the bacteria with the antibiotic-resistant gene previously found in China and Europe.
The mcr-1 gene makes bacteria resistant to the drug colistin, which is used as an antibiotic of last resort.
Colistin has been available since 1959 to treat infections but was abandoned for human use in the 1980s due to high kidney toxicity.
It is widely used in livestock farming, especially in China.
However, colistin has been brought back as a treatment of last resort in hospitals and clinics as bacteria have started developing resistance to other, more modern drugs.
The CDC said an investigation has determined that the Pennsylvania patient did not have a type of bacteria known as carbapenem-resistant enterobacteriaceae (CRE) and it was not resistant to all antibiotics.
"The presence of the mcr-1 gene, however, and its ability to share its colistin resistance with other bacteria such as CRE raise the risk that pan-resistant bacteria could develop," the CDC said.
US health authorities have been looking for the mcr-1 gene in the US since it emerged in China in 2015.
Its discovery in the United States for the first time "heralds the emergence of truly pan-drug resistant bacteria," said a Defense Department report on the finding published last week in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 01 2016 | 5:48 PM IST

Next Story